Every Form 4 that Pediatrix Medical Group, Inc. (MD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MD filings page.
Pediatrix Medical Group, Inc. (MD) director Laura A. Linynsky reported a disposition to the issuer of 6,000 shares of Common Stock on September 10, 2026, at $26.82 per share. After this transaction, she directly holds 33,900 shares. No Rule 10b5-1 trading plan is reported for this transaction.
Pediatrix Medical Group, Inc. (MD) director Sylvia Jean Young reported a disposition of common stock to the issuer. On 2026-08-14, she disposed of 18,500 shares at a weighted average price of $26.62 per share, in multiple transactions executed between $26.51 and $26.80. Following this issuer disposition, she directly holds 29,786 shares of Pediatrix Medical Group common stock.
McEachin Thomas reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Thomas McEachin received a grant of 472 restricted shares of common stock on August 12, 2026 at a reference value of $26.50 per share under the Second Amended and Restated 2008 Incentive Compensation Plan. His directly held shares increased to 7,668, and he also reports 66,073 shares held indirectly through the Thomas A. McEachin Living Trust, with he and his spouse as trustees and beneficiaries. The restricted shares will vest on May 7, 2027.
Weis Shirley A reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group, Inc. reported that director Shirley A. Weis received an equity grant of 472 shares of Common Stock on August 12, 2026. The restricted shares were granted under the company’s Second Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. Following this award, Weis directly holds 19,095 shares of Pediatrix Medical Group common stock.
Starcher John M. Jr. reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group, Inc. reported that director John M. Starcher Jr. received an equity award of 472 shares of common stock on August 12, 2026. These restricted shares, granted under the company’s Second Amended and Restated 2008 Incentive Compensation Plan, will vest on May 7, 2027. Following this grant, Starcher directly holds 73,732 shares of Pediatrix common stock.
Linynsky Laura A reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Laura A. Linynsky received a grant of 472 restricted shares of common stock on August 12, 2026 under the company’s Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to her annual equity award. The restricted shares were valued at $26.50 per share for reporting purposes and will vest on May 7, 2027. Following this grant, Linynsky directly holds 39,900 shares of Pediatrix Medical Group common stock.
Newman Kurt Douglas reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Kurt Douglas Newman received a grant of 472 shares of common stock as a restricted stock award under the company’s Second Amended and Restated 2008 Incentive Compensation Plan. The restricted shares will vest on May 7, 2027, bringing his directly held common stock to 17,405 shares after the award.
Rucker Michael A. reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group, Inc. reported that director Michael A. Rucker received an equity compensation grant of 472 shares of common stock at a value of $26.50 per share. These are restricted shares under the Second Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. Following this award, Rucker holds 66,769 shares of Pediatrix common stock directly.
Young Sylvia Jean reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group, Inc. reported that director Sylvia Jean Young received a grant of 472 restricted shares of common stock on August 12, 2026. The award was granted under the company’s Second Amended and Restated 2008 Incentive Compensation Plan and reflects an increase to her annual equity award. These restricted shares will vest on May 7, 2027, and her directly held common stock position after the grant is 48,286 shares.
SANSONE GUY P reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group, Inc. reported that director Guy P. Sansone received an equity award of 472 shares of Common Stock on August 12, 2026. The restricted shares were granted under the Second Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027, bringing his post-grant direct holdings to 87,416 shares.
Haddock David reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group EVP David Haddock received new equity awards. On 2026-06-22, he was granted 20,036 shares of common stock at no cost as restricted shares under the company’s incentive compensation plan.
He also received 51,000 Performance Share Units, each tied to one common share. These PSUs vest after three years only if both service and stock performance conditions are met. Shares are earned in one-third increments based on Pediatrix’s stock trading at 115%, 125% and 135% of $22.66 for at least 20 consecutive trading days before the third anniversary of the grant date.
Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore reported bona fide gifts of 36,814 shares of common stock. The transactions on June 9, 2026 moved 18,407 shares to a family trust and 18,407 shares from her direct holdings. After these transfers, she holds 78,059 shares directly and 111,831 shares indirectly through the trust, with beneficial interest limited to her pecuniary stake.
Pediatrix Medical Group EVP, CFO and Treasurer Kasandra H. Rossi received 31,800 restricted shares of common stock as an annual equity award under the company’s incentive compensation plan. The award vests 25% on June 1, 2027, 25% on June 1, 2028, and 50% on June 1, 2029. In connection with vesting of prior awards, 3,701 restricted shares were withheld to cover taxes. After these transactions, Rossi directly holds 101,399 common shares.
Pediatrix Medical Group Chief Executive Officer Mark S. Ordan reported a series of equity compensation adjustments and tax-related share withholdings. He received 127,198 restricted shares on June 1, 2026 at no cost under the company’s Second Amended and Restated 2008 Incentive Compensation Plan, tied to an annual equity award. A portion of these restricted shares is scheduled to vest 25% on June 1, 2027, 25% on June 1, 2028 and 50% on June 1, 2029, subject to the plan’s terms.
The filing also shows 19,119 restricted shares of common stock disposed of on June 1, 2026 at a price of $21.54 per share, representing shares withheld to cover taxes upon vesting. In addition, 97,174 restricted shares were granted on June 2, 2026 and 97,174 shares were returned to the issuer the same day. This pair of transactions reflects a revision to a 194,347-share annual equity award originally granted on June 1, 2025 so it complies with the plan’s annual award limitations, while preserving the intended vesting schedule. After these transactions, Ordan directly holds 410,884 shares of Pediatrix Medical Group common stock.
Pediatrix Medical Group EVP and Chief Investment & Strategy Officer Don Gregory Neeb reported routine equity compensation activity. He received a grant of 63,888 restricted shares of common stock under the company’s Second Amended and Restated 2008 Incentive Compensation Plan as part of an annual equity award.
According to the vesting schedule, 25% of these restricted shares will vest on June 1, 2027, 25% on June 1, 2028, and 50% on June 1, 2029, subject to the plan’s terms. In a related tax-withholding disposition, 8,003 restricted shares were withheld to cover taxes upon vesting of shares. After these entries, Neeb directly holds 137,231 Pediatrix common shares.
Pediatrix Medical Group EVP Mary Ann E. Moore reported a routine share withholding for taxes. On the vesting of restricted stock, 11,944 common shares were withheld at $21.54 per share to cover tax obligations, classified as a tax-withholding disposition.
After this event, she directly holds 96,466 common shares. A separate trust, for which she and her spouse serve as trustees, holds 93,424 common shares indirectly; she disclaims beneficial interest in those shares beyond her pecuniary interest.
Pediatrix Medical Group director-linked trust sells shares
A trust associated with director Shirley A. Weis sold 36,028 shares of Pediatrix Medical Group common stock in an open-market transaction at a weighted average price of $23.75 per share, with individual trade prices ranging from $23.55 to $23.85.
The shares were held by The Weis Family Trust, for which Shirley A. Weis and her husband serve as trustees and members of her immediate family are beneficiaries. Following the sale, the trust reported no remaining Pediatrix shares, while Weis directly holds 18,623 shares.
Pediatrix Medical Group director Thomas McEachin reported charitable-style transfers of company stock. On May 13, 2026, he made bona fide gifts totaling 22,854 shares of Pediatrix common stock. One 11,427-share gift involved a trust where he and his spouse serve as trustees and beneficiaries, and another 11,427-share gift involved directly held shares.
After these transactions, McEachin reports indirect ownership of 66,073 shares through the trust and continued direct ownership of 7,196 shares. These are non-cash, gift transfers rather than open-market sales or purchases, and do not change his role as a director.
Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore reported a gift transfer of company stock. On May 11, 2026 she made a bona fide gift of 40,826 shares of Pediatrix common stock to a family trust where she and her spouse serve as trustees and her immediate family members are beneficiaries. Following these transactions, she reports 108,410 shares held directly and 93,424 shares held indirectly through a trust. Moore disclaims beneficial interest in the trust-held shares except to the extent of her pecuniary interest.
Rucker Michael A. reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Michael A. Rucker received a grant of 7,196 shares of common stock as an equity award. The restricted shares were granted at no cash cost under the company’s Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. Following this award, Rucker directly holds 66,297 shares of Pediatrix Medical Group common stock.
Linynsky Laura A reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Laura A. Linynsky received a grant of 7,196 shares of restricted common stock as an annual equity award. The grant was made at no cash cost per share under the company’s Amended and Restated 2008 Incentive Compensation Plan. These restricted shares are scheduled to vest on May 7, 2027, meaning they become fully owned if service conditions are met. Following this award, Linynsky directly holds a total of 39,428 shares of Pediatrix Medical Group common stock.
SANSONE GUY P reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Guy P. Sansone received a grant of 7,196 shares of restricted common stock as an annual equity award. The shares were granted at no cash cost under the company’s Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. Following this award, Sansone directly holds 86,944 shares of Pediatrix Medical Group common stock, reflecting routine stock-based compensation rather than an open-market purchase or sale.
Young Sylvia Jean reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Sylvia Jean Young reported an equity award of common stock. She received 7,196 restricted shares of Pediatrix Medical Group, Inc. common stock on May 7, 2026, as a grant under the company’s Amended and Restated 2008 Incentive Compensation Plan in connection with her annual equity award.
The restricted shares were granted at no cash cost to her and will vest on May 7, 2027, subject to the plan’s terms. After this award, she now directly holds 47,814 shares of Pediatrix common stock, reflecting her ongoing equity-based compensation and alignment with shareholders.
Starcher John M. Jr. reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director John M. Starcher Jr. received an equity grant of 7,196 shares of common stock as a compensation award. The shares were granted at no cash cost to him and increase his direct holdings to 73,260 shares.
These are restricted shares granted under the company’s Amended and Restated 2008 Incentive Compensation Plan in connection with an annual equity award. The restricted stock is scheduled to fully vest on May 7, 2027, meaning the shares become unrestricted for him on that date if vesting conditions are satisfied.
Weis Shirley A reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Shirley A. Weis received 7,196 restricted shares of common stock as an equity grant. The award was made at a price of $0.00 per share under the company’s Amended and Restated 2008 Incentive Compensation Plan in connection with her annual equity award.
These restricted shares are scheduled to vest on May 7, 2027. Following the grant, Weis directly holds 18,623 common shares and is also reported as an indirect owner of 36,028 common shares held by The Weis Family Trust, for which she and her husband serve as trustees and her immediate family members are beneficiaries.
McEachin Thomas reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Thomas McEachin reported an equity grant and updated holdings. He received a grant of 7,196 restricted shares of Common Stock at a price of $0.00 per share as an annual equity award under the Amended and Restated 2008 Incentive Compensation Plan. These restricted shares will vest on May 7, 2027. Following the grant, he directly holds 18,623 common shares. Separately, a trust titled the Thomas A. McEachin Living Trust dated April 17, 2025 holds 54,646 common shares, for which McEachin and his spouse serve as trustees and beneficiaries.
Newman Kurt Douglas reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Kurt Douglas Newman received a grant of 7,196 shares of restricted common stock as an annual equity award. The award was granted at no cash cost to him under the company’s Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. After this grant, he directly holds 16,933 Pediatrix common shares.
Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore reported equity transactions in company common stock. She acquired 39,925 shares on March 1, 2026 as a share award tied to performance conditions from a program established on March 1, 2023.
On the same date, 26,931 shares were withheld to satisfy tax obligations upon vesting of shares at a price of $19.85 per share. After these direct transactions, she held 149,236 shares directly. An additional 52,598 shares are held indirectly through a trust for which she and her spouse serve as trustees.
Pediatrix Medical Group, Inc. reported that its EVP, CFO and Treasurer, Kasandra H. Rossi, had 3,676 shares of common stock withheld on a Form 4 filing. These restricted shares were withheld at $19.85 per share to cover taxes due upon vesting, rather than being sold in the open market.
After this tax-withholding disposition, Rossi directly holds 73,300 shares of Pediatrix common stock. This type of transaction is a routine administrative step tied to equity compensation vesting.
Pediatrix Medical Group, Inc. disclosed that its chief executive officer, who also serves as a director, sold 23,000 shares of Pediatrix common stock on December 15, 2025. The shares were sold at a weighted average price of $22.41 per share, with individual sale prices ranging from $22.00 to $22.62.
After completing this transaction, the insider directly beneficially owned 302,805 shares of Pediatrix common stock. The sale was reported as a disposition of non-derivative securities held directly by the reporting person.
Pediatrix Medical Group, Inc. (MD) reported an insider stock sale by a director. On 11/17/2025, the reporting person sold 10,478 shares of common stock in an open-market transaction coded "S" at a weighted average price of $23.00 per share, with individual trade prices ranging from $23.00 to $23.02.
After this transaction, the director beneficially owns 59,101 shares of Pediatrix common stock in direct form. The filing notes that detailed trade-by-trade pricing within the reported range is available upon request.
Pediatrix Medical Group (MD) reported an insider transaction by a Director. On 11/06/2025, the reporting person sold 10,000 shares of common stock (code S) at a weighted average price of $21.65, with individual trade prices ranging from $21.51 to $21.76.
Following the sale, the reporting person beneficially owned 32,232 shares, held directly. The footnote states the seller will provide full trade-by-trade details within the disclosed price range upon request.